Project Grant HT94252310265
Award Date
5/1/23
Completion Date
4/30/25
Dollars Obligated
$378K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Washington, DC 20057, USA
Similar Awards
The U.S. Defense Health Agency awarded a $624,000 Project Grant to Georgetown University under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "TARGETING OVARIAN STROMAL CELL SENESCENCE TO MITIGATE IR-INDUCED TRANSGENERATIONAL GASTROINTESTINAL CANCER RISK." The grant, with a performance period from July 1, 2024 to June 30, 2026, will support Georgetown's scientific investigation into developing treatments to address the increased risk of...
Georgetown University received a $971,537 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on April 1, 2024, will support research to target cellular senescence and prevent post-traumatic epilepsy. The project will be conducted at Georgetown's facility in Washington, D.C. and is scheduled for completion by March 31, 2027. The Military Medical Research and Development program funds a...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The Defense Health Agency awarded a $159,892 Project Grant to the University of Illinois under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into "Metabolic Vulnerabilities Associated to G12C Inhibitor Resistance" from January 1, 2022 through December 31, 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award will...
This federal Project Grant award in the amount of $780,000.00 was issued by the Defense Health Agency to Georgetown University on June 15, 2025. The award supports the "ENVIRONMENTALLY INDUCED SPERM RNAS AS MEDIATORS OF PLACENTATION, PROGENY, AND MATERNAL HEALTH" research project under the Department of the Army Medical Command's Military Medical Research and Development (CFDA 12.420) program. The research aims to investigate the role of environmentally induced sperm RNAs in...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
The Department of Defense's Defense Health Agency awarded a $1,127,375 Project Grant to The Washington University Office of Sponsored Research Services Division under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from Sep 30, 2023 to Sep 29, 2027, will fund research on "REPLICATION DRIVEN VULNERABILITIES IN CYCLIN E OVEREXPRESSING OVARIAN CANCERS". As a prominent research institution with expertise in biomedical sciences, The Washington...
The Defense Health Agency has awarded a $968,400 Project Grant to Mayo Clinic to develop a personalized approach to treating drug-resistant ovarian cancer. The grant, which began on June 1, 2024, and will run through May 31, 2028, is funded under the Military Medical Research and Development program (CFDA 12.420). This program supports biomedical research to improve the health and care of military service members, veterans, and their families. Through this award, Mayo Clinic will leverage its...
The Defense Health Agency awarded Rutgers, The State University of New Jersey a $942,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support targeted chemotherapeutic and immunotherapeutic research for drug-resistant ovarian cancer. The three-year award beginning April 1, 2023 will fund Rutgers Biomedical and Health Sciences' investigation into medical solutions for this treatment-resistant form of ovarian cancer through innovative research...